Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease-Reference-Cited by-同舟云学术

Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease

Published:2022-09-27 Issue:12 Volume:11 Page:1578-1591
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacom & Syst Pharma

Author:

Hayato Seiichi¹^ORCID,Takenaka Osamu¹,Sreerama Reddy Sree Harsha²,Landry Ishani²,Reyderman Larisa²,Koyama Akihiko²,Swanson Chad²,Yasuda Sanae²,Hussein Ziad³

Affiliation:

1. Eisai Co., Ltd. Tokyo Japan

2. Eisai Inc. Nutley New Jersey USA

3. Eisai Ltd. Hatfield UK

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12862

Reference42 articles.

1. Alzheimer's Association.Alzheimer's disease facts and figures;2021. Available from:https://www.alz.org/media/Documents/alzheimers‐facts‐and‐figures.pdf

2. Predictive value of APOE- 4 allele for progression from MCI to AD-type dementia: a meta-analysis

3. Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease

4. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

5. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics;ACS Pharmacology & Translational Science;2024-09-06

2. Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease;Med;2024-09

3. Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease;CPT: Pharmacometrics & Systems Pharmacology;2024-08-29

4. Chemical signatures delineate heterogeneous amyloid plaque populations across the Alzheimer’s disease spectrum;2024-06-03

5. Identification of Fibrinogen as a Plasma Protein Binding Partner for Lecanemab Biosimilar IgG: Implications for Alzheimer’s Disease Therapy;2024-05-01